Impact of sublingual immunotherapy with a five-grass pollen tablet on grass pollen allergic rhinitis and asthma: a real-life, long-term analysis in France.

2018 ◽  
Author(s):  
Philippe Devillier
Keyword(s):  
Allergic Rhinitis ◽  
Grass Pollen ◽  
Sublingual Immunotherapy ◽  
Real Life ◽  
Term Analysis

scholarly journals Long-Term Impact of Grass-Pollen (GP) Sublingual Immunotherapy Tablet (SLIT) on Allergic Rhinitis (AR) and on Allergic Asthma (AA) Onset and Progression

2017 ◽  
Vol 20 (9) ◽  
pp. A639-A640
Author(s):  
P Devillier ◽  
M Molimard ◽  
P Demoly ◽  
X Ansolabehere ◽  
I Bardoulat ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Allergic Asthma ◽  
Grass Pollen ◽  
Sublingual Immunotherapy ◽  
Long Term Impact

scholarly journals Quality of life improvement after a three-year course of sublingual immunotherapy in patients with house dust mite and grass pollen induced allergic rhinitis: results from real-life

2017 ◽  
Vol 15 (1) ◽  
Author(s):  
Silviya Mihaylova Novakova ◽  
Maria Toncheva Staevska ◽  
Plamena Ivanova Novakova ◽  
Manuela Dimitrova Yoncheva ◽  
Maria Stoykova Bratoycheva ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Allergic Rhinitis ◽  
House Dust ◽  
House Dust Mite ◽  
Grass Pollen ◽  
Sublingual Immunotherapy ◽  
Real Life ◽  
Dust Mite ◽  
Life Improvement

scholarly journals Patient needs and benefits of sublingual immunotherapy for grass pollen-induced allergic rhinitis: an observational study

Immunotherapy ◽  
2021 ◽  
Author(s):  
Toni Maria Klein ◽  
Meike Hadler ◽  
Matthias Augustin ◽  
Christine Blome
Keyword(s):  
Allergic Rhinitis ◽  
Grass Pollen ◽  
Sublingual Immunotherapy ◽  
Leisure Activities ◽  
Age Groups ◽  
Real Life ◽  
Patient Characteristics ◽  
Patient Needs ◽  
Patient Benefit ◽  
Specific Patient

Aim: Clinical efficacy of sublingual immunotherapy for grass pollen-induced allergic rhinitis (AR) needs to translate into patient benefit. Patients & methods: Patients received Oralair (Stallergenes, Antony, France) in real-life medical practice. Patient-relevant treatment benefits were measured with the AR-specific Patient Benefit Index. Subgroups were analyzed regarding distinct patient characteristics. Results: Data of 883 patients (children, adolescents, and adults) were analyzed. The highest-ranked patient needs referred to having less AR-symptoms, being able to go outdoors, and being free in the choice of leisure activities. Most patients (89.2–94.6%) attained at least minimally relevant benefit. All subgroups reported relevant benefits, with significantly higher scores in some subgroups. Conclusion: Treatment with Oralair was associated with considerable patient-relevant benefit in all age groups.

Grass pollen sublingual immunotherapy and paediatric allergic rhinitis: A patient-oriented decision

2016 ◽  
Vol 44 (4) ◽  
pp. 382-386
Author(s):  
Stefano Miceli Sopo ◽  
Andrea Battista ◽  
Monica Greco ◽  
Serena Monaco
Keyword(s):  
Allergic Rhinitis ◽  
Grass Pollen ◽  
Sublingual Immunotherapy
Sign in / Sign up

Export Citation Format

Share Document